Nearly 5% of adults with type 2 diabetes and obesity may have obstructive sleep apnea, which is more prevalent among those with obesity regardless of diabetes status compared with the general population, according to findings published in Diabetic Medicine.
Adults who develop obesity after having elevated childhood BMI are at higher risk for type 2 diabetes compared with those who avoid obesity regardless of childhood BMI status, according to findings presented at the European Congress on Obesity.
An insulin patch can safely provide similarly effective glycemic management in adults with type 2 diabetes compared with a standard insulin pen, according to findings published in Diabetes Technology & Therapeutics.
Barriers to mealtime insulin include complexity, fear of injections, and lifestyle interference. This multicenter, randomized controlled trial evaluated efficacy, safety, and self-reported outcomes in adults with type 2 diabetes, inadequately controlled on basal insulin, initiating and managing mealtime insulin with a wearable patch versus an insulin pen.
Hydroxychloroquine (HCQ, Plaquenil) might be a candidate as adjunctive therapy in type 2 diabetes, researchers reported here.
Men and women with type 2 diabetes (T2D) have an increased risk for overall cancer and some site-specific cancers, according to a study published online May 9 in the Journal of Diabetes.
Adults with type 2 diabetes inadequately controlled with a DPP-IV inhibitor plus metformin therapy experienced an improvement in glycemic control with the antimalarial drug hydroxychloroquine that was similar to the SGLT2 inhibitor canagliflozin, according to study data presented here.
Adults with type 2 diabetes who also have stiffer arteries are more likely to experience stroke and vascular mortality than those without such arterial stiffness, according to findings presented in Diabetic Medicine.
Adults with type 2 diabetes may be able to achieve sustainable remission from the disease by losing weight and decreasing fat in the pancreas and liver, according to data presented at the AACE Annual Scientific and Clinical Congress.
Treatment with linagliptin in patients with type 2 diabetes and cardiovascular and/or kidney disease had no impact on risk for cardiovascular or kidney events.